Home › NDC Lookup › RxCUI directory › RxCUI 1999007

1 ML angiotensin II 2.5 MG/ML Injection — RxCUI 1999007

RxNorm drug concept · Semantic clinical drug
RxCUI 1999007 Semantic clinical drug · SCD ● Current RxNorm concept 3 FDA products 3 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI1999007
Official name1 ML angiotensin II 2.5 MG/ML Injection
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
Also known asangiotensin II 2.5 MG per 1 ML Injection; angiotensin II 2.5 MG in 1 ML Injection
FDA products mapped3
Package NDCs mapped3
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

🕸️ Concept Web — How 1 ML angiotensin II 2.5 MG/ML Injection Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept 1 ML angiotensin II 2.5 MG/ML Injection RxCUI 1999007

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Angiotensin II 1999003
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Giapreza 1999008
  3. Dose forms 6

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Angiotensin II Injection 1999006
    • Angiotensin II Injectable Product 1999005
    • Angiotensin II Injection [Giapreza] 1999010
    • Giapreza Injectable Product 1999011
    • Injection 1649574
    • Injectable Product 1151126
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 11 of 11 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Angiotensin II 2.5 MG/ML SCDC · 1999004
  • Angiotensin II Injection SCDF · 1999006
  • Angiotensin II Injectable Product SCDG · 1999005

Brand-Name Concepts

📦 FDA Products & Package NDCs

3 products · 3 package NDCs
3 package NDCs map to RxCUI 1999007 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
68083-0553-01 1 VIAL, SINGLE-DOSE in 1 CARTON (68083-553-01) / 1 mL in 1... ANGIOTENSIN II Gland Pharma Limited 2025-06-03
68547-0005-01 1 VIAL, SINGLE-DOSE in 1 CARTON (68547-005-01) / 1 mL in 1... Giapreza La Jolla Pharmaceutical Company 2022-09-15
68547-0501-02 1 VIAL, SINGLE-DOSE in 1 CARTON (68547-501-02) / 1 mL in 1... Giapreza La Jolla Pharmaceutical Company 2018-02-05
Observed labelers: La Jolla Pharmaceutical Company (2) · Gland Pharma Limited (1) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.